Sofosbuvir, Velpatasvir, And Voxilaprevir

Introduction Overview

Generic Name

sofosbuvir, velpatasvir, and voxilaprevir

Brand Name

Vosevi

Dosage Form

Oral tablet

Drug Class

Antiviral combinations

Pharmacokinetics

Absorption:
Vosevi is administered orally as a fixed-dose combination tablet containing sofosbuvir, velpatasvir, and voxilaprevir. The presence of food significantly enhances the bioavailability of voxilaprevir, the protease inhibitor component, therefore, administration with food is recommended to optimize systemic exposure. Sofosbuvir and velpatasvir exhibit high oral bioavailability and are rapidly absorbed, with peak plasma concentrations reached generally within 1 to 4 hours post-dose. The solubility and absorption of the component drugs may be influenced by gastric pH and concomitant use of gastric acid-reducing agents.

Distribution:
The three active components demonstrate moderate plasma protein binding: sofosbuvir approximately 61-65%, velpatasvir approximately 99.5%, and voxilaprevir about 99.9%. This high protein binding, particularly for voxilaprevir and velpatasvir, contributes to their pharmacodynamics and tissue distribution. Sofosbuvir and its metabolite GS-331007 distribute extensively into tissues. The volume of distribution varies among components but generally indicates wide tissue penetration, including the liver, the target organ for hepatitis C virus.

Metabolism:
Sofosbuvir is a nucleotide analog prodrug undergoing intracellular metabolism to its active nucleoside triphosphate form. It is predominantly metabolized via intracellular enzymatic conversion rather than cytochrome P450 pathways, limiting its potential for significant CYP-mediated drug interactions. Velpatasvir and voxilaprevir are primarily metabolized via cytochrome P450 enzymes; velpatasvir mainly through CYP2B6, CYP2C8, and CYP3A4, and voxilaprevir mainly via CYP3A. Both also undergo biliary excretion of metabolites. This metabolic profile necessitates caution with concomitant use of strong CYP3A inducers or inhibitors.

Elimination:
Sofosbuvir’s predominant circulating metabolite GS-331007 is eliminated primarily via renal excretion. Velpatasvir and voxilaprevir are mainly eliminated via the fecal route through biliary excretion, with minimal renal clearance. Their half-lives support once-daily dosing, with sofosbuvir having a half-life of approximately 0.5 hours for the parent compound, but the active metabolite GS-331007 has a longer half-life (~27 hours). Velpatasvir and voxilaprevir have half-lives of approximately 15 and 30 hours, respectively, supporting sustained antiviral activity. Hepatic impairment can affect the pharmacokinetics of voxilaprevir, highlighting the importance of patient selection.

Dosage Forms

Available Dosage Forms:
Vosevi is available as an oral tablet containing a fixed-dose combination of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg.

Dosages for Adults and Adolescents:
The recommended dosage is one tablet taken orally once daily with food for 12 weeks. This dosing regimen applies to adult patients with chronic hepatitis C infection across genotypes 1 through 6 who have previously been treated with NS5A inhibitors or sofosbuvir-containing regimens without NS5A inhibitors, as per FDA-approved indications. Clinical trials support the 12-week duration to maximize sustained virologic response.

Specific Patient Populations:
Vosevi is approved for adults with chronic hepatitis C without cirrhosis or with compensated cirrhosis (Child-Pugh class A). It is not recommended in patients with decompensated cirrhosis (Child-Pugh B or C) due to limited data and potential for increased drug exposure with voxilaprevir. Caution is advised in patients with moderate to severe hepatic impairment. Safety and efficacy have not been established in pediatric populations under 18 years. Patients with renal impairment, including those on dialysis, can use Vosevi without dosage adjustment since sofosbuvir's metabolite is renally cleared, but careful monitoring is advised. Use in pregnancy is not well-studied; potential risks and benefits should be evaluated. Patients on concomitant medications, especially those that induce CYP3A4 or P-glycoprotein, should be evaluated for potential drug interactions influencing dosage considerations.

Mechanism Of Action

Vosevi is a fixed-dose combination antiviral therapy combining three agents with complementary mechanisms targeting different stages of the hepatitis C virus (HCV) lifecycle to achieve potent viral suppression and clearance. Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, acting as a chain terminator upon incorporation into viral RNA, thus inhibiting viral genome replication. This mechanism directly impairs the synthesis of viral RNA, halting the proliferation of HCV.

Velpatasvir is an inhibitor of the NS5A protein, a multifunctional phosphoprotein essential for viral RNA replication and virion assembly. By binding to NS5A, velpatasvir disrupts the viral replication complex formation and impedes assembly and release of infectious viral particles, providing a critical blockade at a replication and assembly stage.

Voxilaprevir is a potent inhibitor of the NS3/4A protease, an enzyme responsible for cleavage of the HCV polyprotein into mature functional proteins necessary for viral replication. Inhibition of this protease prevents viral protein maturation, thereby impairing viral replication.

The combination of these three agents offers a high barrier to resistance development and coverage across all major HCV genotypes (1 through 6). Clinically, this triple combination is specifically indicated for patients with chronic hepatitis C infection who have failed previous direct-acting antiviral therapies, especially those with prior NS5A inhibitor treatment. Pharmacological synergy among sofosbuvir, velpatasvir, and voxilaprevir ensures enhanced viral eradication compared to monotherapies or dual therapies, resulting in improved sustained virologic response rates.

Pharmacological Actions

Inhibition of HCV NS5B RNA polymerase by sofosbuvir, leading to termination of viral RNA synthesis.
Inhibition of HCV NS5A protein by velpatasvir, disrupting viral replication complex and virion assembly.
Inhibition of HCV NS3/4A protease by voxilaprevir, preventing viral polyprotein processing.
Broad genotype coverage (1-6) for chronic hepatitis C virus.
Potent antiviral action against treatment-experienced patients with resistant HCV strains.
High barrier to resistance development due to multi-target inhibition.
Reduced viral replication and viral load leading to eradication of chronic infection.
Synergistic interaction of the three agents for enhanced efficacy.
Minimal direct activity against HIV or other viruses, specific to HCV.
Supports rapid virologic response and reduces progression of liver disease.
Adjunct to liver health management by controlling viral replication.
Effective in patients with compensated cirrhosis (Child-Pugh A).
Oral once daily administration promotes adherence.
Metabolic and excretory profiles limit systemic toxicity.
Limited induction or inhibition of major CYP450 enzymes helps reduce drug-drug interactions.

Therapeutic Or Clinical Uses

Treatment of chronic hepatitis C virus (HCV) infection in adults.
Indicated for HCV genotypes 1, 2, 3, 4, 5, and 6 infections.
Used in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Approved for patients previously treated with NS5A inhibitor-containing regimens who experienced treatment failure.
Approved for patients with genotype 1a or 3 infections previously treated with sofosbuvir-containing regimens without NS5A inhibitors.
Therapeutic option after failure of prior direct-acting antiviral therapies.
Treatment to prevent progression to liver fibrosis, cirrhosis, or hepatocellular carcinoma.
Part of a strategy to achieve sustained virologic response (SVR) and virologic cure.
Used to reduce viral replication and risk of HCV-related liver complications.
May be used in HCV/HIV coinfected patients (not a treatment for HIV).
Supports reduction of liver inflammation linked to chronic HCV infection.
Helps decrease hepatic viral reservoir to improve liver function.
Component of comprehensive hepatitis C treatment guidelines internationally.
Oral therapy simplifies treatment compared to interferon-based regimens.
Used in special populations under careful monitoring, including those with renal impairment.

Side Or Adverse Effects

Common adverse effects include headache, fatigue, and nausea.
Occasional diarrhea reported during therapy.
Rare but serious allergic reactions such as urticaria, angioedema, or anaphylaxis.
Potential for serious liver injury including signs of hepatotoxicity: right upper quadrant pain, jaundice, dark urine, or unexplained bleeding.
Risk of reactivation or worsening of hepatitis B infection during or after treatment.
Cardiac adverse events when coadministered with amiodarone, including bradycardia, heart block, and syncope.
Elevations in liver enzymes during treatment necessitating monitoring.
Gastrointestinal disturbances including vomiting and loss of appetite.
Fatigue and asthenia more frequently reported in patients with advanced liver disease.
Rare instances of anemia or hematologic changes in treated patients.
Potential for hypersensitivity reactions to active ingredients or excipients.
Risk of drug-induced liver injury heightened in patients with pre-existing liver conditions.
Neurological symptoms such as dizziness or light-headedness have been reported.
Injection site reactions are not applicable due to oral administration.
Discontinuation due to adverse events is rare but possible with close monitoring.

Precautions

Monitor patients for hepatitis B virus reactivation before and during therapy.
Avoid use with strong CYP3A inducers, including rifampin, to prevent loss of efficacy.
Use caution in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Perform liver function tests regularly during and for several months post-treatment.
Evaluate renal function, especially in patients with pre-existing kidney disease or on dialysis.
Advise patients to take medication with food to enhance absorption and reduce side effects.
Avoid concomitant use of antacids within 4 hours of dosing to prevent reduced drug exposure.
Consider drug-drug interaction potential with warfarin and other anticoagulants; monitor INR closely.
Pregnancy safety has not been established; weigh potential benefits against risks before prescribing.
Breastfeeding is not recommended during treatment due to unknown risks.
Do not share medication; use only as prescribed by healthcare provider.
Maintain consistent dosing schedule to ensure therapeutic effectiveness.
Monitor for signs of liver decompensation or worsening hepatic function.
Educate patients about safe practices to prevent HCV transmission during therapy.
Inform patients about the importance of completing the full 12-week treatment course.

Warnings

Risk of hepatitis B virus reactivation leading to fulminant hepatitis, hepatic failure, and death.
Contraindicated in patients currently taking rifampin due to significant drug interactions.
Serious liver injury reported rarely; discontinue immediately if clinical signs occur.
May cause bradycardia when taken concomitantly with amiodarone; avoid co-administration.
Not effective against HIV; patients co-infected require separate HIV therapy.
Use with caution in patients with advanced liver disease; limited safety data available.
Potential interactions with multiple drug classes necessitate careful review of concomitant medications.
Women who are pregnant or planning pregnancy should consider alternative therapies.
Avoid in patients with known hypersensitivity to any components of Vosevi.
Avoid use in pediatric patients; safety and efficacy not established.
Serious allergic reactions may occur; seek immediate medical attention if symptoms arise.
May exacerbate liver dysfunction in patients with decompensated cirrhosis.
Do not discontinue therapy prematurely to prevent viral resistance.
Patients should be monitored closely for signs of drug-induced liver injury.
Not recommended in patients with end-stage renal disease without specialist oversight.

Contraindication

Known hypersensitivity to sofosbuvir, velpatasvir, voxilaprevir, or any tablet excipients.
Concurrent use of rifampin or other strong inducers of CYP3A4, CYP2B6, CYP2C8, or P-glycoprotein.
Patients with decompensated cirrhosis (Child-Pugh B or C) due to increased drug exposure risks.
Use in patients with co-administered amiodarone without strict cardiac monitoring is contraindicated.
Combination with drugs with significant drug-drug interaction potential contraindicated unless no alternatives.
Known severe renal impairment without medical oversight.
Not approved for use in pediatric patients under 18 years of age.
Contraindicated in patients with active hepatitis B infection not under suppressive therapy.
Patients who have previously demonstrated intolerance to components of the combination during prior treatments.
Use with caution or contraindicated in pregnant patients due to limited safety data.

Drug Interactions

Rifampin and other strong CYP3A4 inducers significantly reduce the plasma concentrations of voxilaprevir and velpatasvir, leading to loss of efficacy.
Amiodarone coadministration increases risk of symptomatic bradycardia and cardiac conduction abnormalities.
Antacids containing aluminum or magnesium should be avoided within 4 hours of Vosevi dosing to prevent decreased absorption.
Concomitant use with warfarin or other vitamin K antagonists requires frequent INR monitoring due to possible interaction.
Interactions with P-glycoprotein inducers or inhibitors may alter drug levels of Vosevi components.
Drugs metabolized by CYP450 enzymes, including statins, benzodiazepines, and certain antidepressants, may have altered plasma concentrations.
Effectiveness of hormonal contraceptives may be affected by drug interactions; alternative or additional contraceptive methods may be recommended.
Coadministration with other direct-acting antivirals not containing compatible components may lead to adverse events or reduced efficacy.
Careful review of herbal supplements or over-the-counter products is advised to avoid interactions.
Drugs affecting gastric pH (e.g., proton pump inhibitors) may alter velpatasvir absorption; dosing adjustments or spacing may be necessary.
Immunosuppressants like tacrolimus and cyclosporine may interact, requiring monitoring.
Avoid use with strong CYP2B6 or CYP2C8 inducers or inhibitors that may influence velpatasvir metabolism.
Concomitant use with other protease inhibitors for HIV or hepatitis B is generally not recommended.
Potential interactions with antiarrhythmics, anticonvulsants, and antipsychotics require clinical oversight.
Monitoring for adverse reactions is essential when starting, stopping, or changing doses of interacting drugs.

Preparations Of The Drug

Vosevi is formulated as a fixed-dose combination oral tablet containing 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir.
Tablets are film-coated for oral administration.
Supplied in bottles or blister packs to maintain stability and protect from moisture.
Stable at room temperature when stored in the original container, away from heat and moisture.
Each tablet is administered once daily with food to optimize absorption and efficacy.
The formulation ensures simultaneous delivery of all three antiviral agents.
Designed for convenient once-daily dosing to improve patient adherence.
Contains excipients that support tablet integrity and bioavailability without compromising safety.
No injectable or alternative dosage forms are currently available.
Packaging includes patient information leaflets emphasizing dosing instructions and safety guidance.
Manufactured under stringent quality control to assure potency and purity.
Packaging is child-resistant with clear labeling.
Shelf life generally extends to 24 months from manufacture when stored properly.
Generic formulations of this combination are not widely available; proprietary brand Vosevi is standard.
Formulation optimized to reduce pill burden in hepatitis C therapy.